Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phentolamine infusion in chronic coronary syndrome and chronic kidney disease
PACTR202209493847741Phase 1Completed
- Sponsor
- Dr. Mohamed Abo Hamila
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of phentolamine in chronic kidney disease (CKD) and Chronic Coronary Syndrome (CCS) (2 arms), sponsored by Dr. Mohamed Abo Hamila. Primary endpoints: Postprocedural urine output improvement, Prevention of contrast-induced nephropathy-acute kidney injury and 1 more. Started Oct 2016; status: completed.
02
Drugs
phentolamine
03
Conditions
chronic kidney disease (CKD)Chronic Coronary Syndrome (CCS)
Beyond the preview
Go deeper on PACTR202209493847741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202209493847741.